Felbamate, an anti-convulsive drug, has anti-parkinsonian potential in rats.
The potency of felbamate, an anti-convulsive drug, to influence dopamine D1 (SCH 23390) and D2 (haloperidol) receptor-mediated catalepsy (akinesia and bradykinesia) was studied in rats. In the catalepsy test, felbamate antagonized dopamine D2 receptor- but not D1 receptor-induced akinesia. Bradykinesia in the open field was never influenced. The results demonstrate that felbamate has similar anti-parkinsonian potential as glycine site antagonists blocking the N-methyl-D-aspartate (NMDA) receptor complex.
Kretschmer
B D
BD
Department of Neuropharmacology, University of Tübingen, Germany.
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001552:Benzazepines / Q000494:pharmacology; D002375:Catalepsy / Q000139:chemically induced; D065127:Dopamine D2 Receptor Antagonists; D004409:Dyskinesia, Drug-Induced / Q000517:prevention & control; D000078328:Felbamate; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D048448:Phenylcarbamates; D011409:Propylene Glycols / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors
D000927:Anticonvulsants; D000978:Antiparkinson Agents; D001552:Benzazepines; D065127:Dopamine D2 Receptor Antagonists; D048448:Phenylcarbamates; D011409:Propylene Glycols; D017447:Receptors, Dopamine D1; D006220:Haloperidol; D000078328:Felbamate